Chimeric Therapeutics (ASX:CHM) hits critical milestone advancing CHM 2101 to clinical study - Kalkine Media

Highlights

• Chimeric Therapeutics has achieved a critical stage that is considered the backbone for CAR T cell therapy development
• The timely completion of manufacturing and quality release of viral vector would support the CHM 2101 therapy's Phase 1A clinical trial
• CHM 2101 was invented at the University of Pennsylvania, with preclinical evidence published last year

ASX-listed clinical-stage cell therapy company Chimeric Therapeutics (ASX: CHM) -- developing various cellular therapies for cancer treatment -- has reported a significant milestone. The company has achieved manufacturing and quality release of viral vector for its autologous CAR T cell therapy CHM 2101.

The cell therapy is presently in preclinical development stage, with the Phase 1A clinical trial planned for gastrointestinal and neuroendocrine tumours.

Key milestone advancing CHM 2101 toward the clinic

The timely completion of manufacturing and quality release of viral vector is considered a critical stage and one of the biggest challenges in cellular therapy technical operations. Viral vector holds genetic engineering instructions, which Chimeric says makes it the backbone for the manufacture of CAR T therapy.

Chimeric has further asserted that the prevailing shortage of vector manufacturing capacity has hit development programs of many cell therapy focused companies, thereby leading to challenges for commercial producers.

The completion is being cited by Chimeric as a “key milestone” that can advance its CHM 2101 toward the clinic.

Source: CHM ASX release dated 9 March 2023

CHM 2101

The University of Pennsylvania, the world-renowned cell therapy centre, has invented this autologous CAR T cell therapy.

The “first in class”, third generation autologous CAR T cell therapy of Chimeric has demonstrated “strong” preclinical evidence of efficacy, with full eradication of eight types of gastrointestinal cancers. The data has highlighted that the efficacy could be achieved with no relapse or toxicity. The therapy, presently in the preclinical development stage, would advance toward Phase 1A clinical trial (gastrointestinal and neuroendocrine tumours), Chimeric has stated.

In a separate press release early in March 2023, Chimeric had updated about the fourth dose cohort in its other cellular therapy CHM 1101 (CLTX CAR T). Read more.

ASX-listed CHM shares traded at AU$0.061 midday on 17 March 2023.